Information Provided By:
Fly News Breaks for October 12, 2016
DHR
Oct 12, 2016 | 08:51 EDT
Evercore ISI analyst Ross Muken is not surprised by Danaher's (DHR) acquisition of Phenomenex saying it is one of the "great consumable assets that remained in Life Science Tools." Muken said the deal terms are "remarkably attractive" and estimates Danaher paid more than $700M for Phenomenex He said revenues are close to $200M, implying an EV/EBITDA multiple in the low to mid-teens, and ROIC north of 10% by year 5, and imply year 1 accretion of 3-5c, and 10-15c by year 5. Muken rates Danaher a Buy with an $89 price target on shares.
News For DHR From the Last 2 Days
DHR
Apr 24, 2024 | 06:40 EDT
Baird raised the firm's price target on Danaher to $271 from $259 and keeps an Outperform rating on the shares. The firm said they reported 1Q results above expectations, helped by respiratory testing and bioprocessing upside. The company saw encouraging bioprocessing trends, with orders growing mid-single-digits, and noted normalization of large customer ordering patterns, with management expecting destocking to be largely complete by 2Q24-end.
DHR
Apr 24, 2024 | 05:28 EDT
Barclays raised the firm's price target on Danaher to $270 from $260 and keeps an Equal Weight rating on the shares post the Q1 report. The company's orders came in above expectations, the analyst tells investors in a research note. The firm says bioprocessing names continue to be favored by investors and that it does not see this changing in the near term.
DHR
Apr 23, 2024 | 09:56 EDT
Notable gainers among liquid option names this morning include Globe Life (GL) $71.33 +4.94, Super Micro (SMCI) $764.85 +47.83, Danaher (DHR) $250.88 +14.79, Kimberly Clark (KMB) $136.87 +7.94, and General Motors (GM) $45.38 +2.17.
DHR
Apr 23, 2024 | 09:04 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here